Simple and rapid analysis of tocilizumab using HPLC-fluorescence detection method.
Identifieur interne : 000843 ( Main/Exploration ); précédent : 000842; suivant : 000844Simple and rapid analysis of tocilizumab using HPLC-fluorescence detection method.
Auteurs : Makoto Takada [Japon] ; Yoshihito Ohba [Japon] ; Seitaro Kamiya [Japon] ; Tsutomu Kabashima [Japon] ; Kenichiro Nakashima [Japon]Source :
- Luminescence : the journal of biological and chemical luminescence [ 1522-7243 ] ; 2019.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (sang), Anticorps monoclonaux humanisés (usage thérapeutique), Chromatographie en phase liquide à haute performance (), Chromatographie en phase liquide à haute performance (instrumentation), Fluorescence, Humains, Polyarthrite rhumatoïde (sang), Polyarthrite rhumatoïde (traitement médicamenteux).
- MESH :
- sang : Anticorps monoclonaux humanisés, Chromatographie en phase liquide à haute performance, Polyarthrite rhumatoïde.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Anticorps monoclonaux humanisés.
- Chromatographie en phase liquide à haute performance, Fluorescence, Humains.
English descriptors
- KwdEn :
- MESH :
- chemical , blood : Antibodies, Monoclonal, Humanized.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- blood : Arthritis, Rheumatoid.
- drug therapy : Arthritis, Rheumatoid.
- instrumentation : Chromatography, High Pressure Liquid.
- methods : Chromatography, High Pressure Liquid.
- Fluorescence, Humans.
Abstract
We developed a novel assay using high-performance liquid chromatography (HPLC) with fluorescence detection for the determination of tocilizumab (TCZ), after it has undergone a facile and rapid pretreatment. TCZ belongs to the same subclass as IgG1 (Immunoglobulin G subclass 1), and we could separate TCZ from IgG1 without antigen-antibody reactions, with the novel detection method. The separation of these antibodies was achieved by pretreatment with an organic solvent containing a base, such as trimethylamine and triethylamine. The effect of these bases on the separation of TCZ is related to the hydrophobicity of the base rather than the electrostatic charge. The results indicated that the surface charge of antibodies changed because of the structural change, even though the difference in the amino acid sequences of the antibodies was very low. Our method is available for the separation of the antibody subclasses, and it would be useful to assay TCZ in blood.
DOI: 10.1002/bio.3615
PubMed: 30809900
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000482
- to stream PubMed, to step Curation: 000482
- to stream PubMed, to step Checkpoint: 000338
- to stream Ncbi, to step Merge: 001E24
- to stream Ncbi, to step Curation: 001E24
- to stream Ncbi, to step Checkpoint: 001E24
- to stream Main, to step Merge: 000843
- to stream Main, to step Curation: 000843
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Simple and rapid analysis of tocilizumab using HPLC-fluorescence detection method.</title><author><name sortKey="Takada, Makoto" sort="Takada, Makoto" uniqKey="Takada M" first="Makoto" last="Takada">Makoto Takada</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Ohba, Yoshihito" sort="Ohba, Yoshihito" uniqKey="Ohba Y" first="Yoshihito" last="Ohba">Yoshihito Ohba</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Kamiya, Seitaro" sort="Kamiya, Seitaro" uniqKey="Kamiya S" first="Seitaro" last="Kamiya">Seitaro Kamiya</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Kabashima, Tsutomu" sort="Kabashima, Tsutomu" uniqKey="Kabashima T" first="Tsutomu" last="Kabashima">Tsutomu Kabashima</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Nakashima, Kenichiro" sort="Nakashima, Kenichiro" uniqKey="Nakashima K" first="Kenichiro" last="Nakashima">Kenichiro Nakashima</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30809900</idno><idno type="pmid">30809900</idno><idno type="doi">10.1002/bio.3615</idno><idno type="wicri:Area/PubMed/Corpus">000482</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000482</idno><idno type="wicri:Area/PubMed/Curation">000482</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000482</idno><idno type="wicri:Area/PubMed/Checkpoint">000338</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000338</idno><idno type="wicri:Area/Ncbi/Merge">001E24</idno><idno type="wicri:Area/Ncbi/Curation">001E24</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E24</idno><idno type="wicri:Area/Main/Merge">000843</idno><idno type="wicri:Area/Main/Curation">000843</idno><idno type="wicri:Area/Main/Exploration">000843</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Simple and rapid analysis of tocilizumab using HPLC-fluorescence detection method.</title><author><name sortKey="Takada, Makoto" sort="Takada, Makoto" uniqKey="Takada M" first="Makoto" last="Takada">Makoto Takada</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Ohba, Yoshihito" sort="Ohba, Yoshihito" uniqKey="Ohba Y" first="Yoshihito" last="Ohba">Yoshihito Ohba</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Kamiya, Seitaro" sort="Kamiya, Seitaro" uniqKey="Kamiya S" first="Seitaro" last="Kamiya">Seitaro Kamiya</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Kabashima, Tsutomu" sort="Kabashima, Tsutomu" uniqKey="Kabashima T" first="Tsutomu" last="Kabashima">Tsutomu Kabashima</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Nakashima, Kenichiro" sort="Nakashima, Kenichiro" uniqKey="Nakashima K" first="Kenichiro" last="Nakashima">Kenichiro Nakashima</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo City, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author></analytic><series><title level="j">Luminescence : the journal of biological and chemical luminescence</title><idno type="eISSN">1522-7243</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (blood)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Arthritis, Rheumatoid (blood)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Chromatography, High Pressure Liquid (instrumentation)</term><term>Chromatography, High Pressure Liquid (methods)</term><term>Fluorescence</term><term>Humans</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (sang)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Chromatographie en phase liquide à haute performance ()</term><term>Chromatographie en phase liquide à haute performance (instrumentation)</term><term>Fluorescence</term><term>Humains</term><term>Polyarthrite rhumatoïde (sang)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Chromatography, High Pressure Liquid</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chromatography, High Pressure Liquid</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Chromatographie en phase liquide à haute performance</term><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Fluorescence</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Chromatographie en phase liquide à haute performance</term><term>Fluorescence</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We developed a novel assay using high-performance liquid chromatography (HPLC) with fluorescence detection for the determination of tocilizumab (TCZ), after it has undergone a facile and rapid pretreatment. TCZ belongs to the same subclass as IgG1 (Immunoglobulin G subclass 1), and we could separate TCZ from IgG1 without antigen-antibody reactions, with the novel detection method. The separation of these antibodies was achieved by pretreatment with an organic solvent containing a base, such as trimethylamine and triethylamine. The effect of these bases on the separation of TCZ is related to the hydrophobicity of the base rather than the electrostatic charge. The results indicated that the surface charge of antibodies changed because of the structural change, even though the difference in the amino acid sequences of the antibodies was very low. Our method is available for the separation of the antibody subclasses, and it would be useful to assay TCZ in blood.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Takada, Makoto" sort="Takada, Makoto" uniqKey="Takada M" first="Makoto" last="Takada">Makoto Takada</name></noRegion><name sortKey="Kabashima, Tsutomu" sort="Kabashima, Tsutomu" uniqKey="Kabashima T" first="Tsutomu" last="Kabashima">Tsutomu Kabashima</name><name sortKey="Kamiya, Seitaro" sort="Kamiya, Seitaro" uniqKey="Kamiya S" first="Seitaro" last="Kamiya">Seitaro Kamiya</name><name sortKey="Nakashima, Kenichiro" sort="Nakashima, Kenichiro" uniqKey="Nakashima K" first="Kenichiro" last="Nakashima">Kenichiro Nakashima</name><name sortKey="Ohba, Yoshihito" sort="Ohba, Yoshihito" uniqKey="Ohba Y" first="Yoshihito" last="Ohba">Yoshihito Ohba</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000843 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000843 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30809900
|texte= Simple and rapid analysis of tocilizumab using HPLC-fluorescence detection method.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30809900" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |